Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $5.2 million.

  • Intellia Therapeutics' Treasury Shares fell 379.49% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 379.49%. This contributed to the annual value of $5.5 million for FY2024, which is 3725.55% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Treasury Shares stood at $5.2 million, which was down 379.49% from $5.3 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Treasury Shares high stood at $5.7 million for Q1 2024, and its period low was $442740.0 during Q1 2021.
  • For the 5-year period, Intellia Therapeutics' Treasury Shares averaged around $3.3 million, with its median value being $4.0 million (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Treasury Shares surged by 33487.91% in 2022, and later crashed by 379.49% in 2025.
  • Intellia Therapeutics' Treasury Shares (Quarter) stood at $453026.0 in 2021, then soared by 328.54% to $1.9 million in 2022, then skyrocketed by 108.19% to $4.0 million in 2023, then soared by 37.26% to $5.5 million in 2024, then dropped by 5.48% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.3 million for Q2 2025, and $5.5 million during Q1 2025.